GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hanall Biopharma Co Ltd (XKRX:009420) » Definitions » Book Value per Share

Hanall Biopharma Co (XKRX:009420) Book Value per Share : ₩3,673.45 (As of Dec. 2023)


View and export this data going back to 1989. Start your Free Trial

What is Hanall Biopharma Co Book Value per Share?

Hanall Biopharma Co's book value per share for the quarter that ended in Dec. 2023 was ₩3,673.45.

During the past 12 months, Hanall Biopharma Co's average Book Value Per Share Growth Rate was 10.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 1.20% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 8.50% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Hanall Biopharma Co was 24.00% per year. The lowest was -6.40% per year. And the median was 6.45% per year.

Hanall Biopharma Co's current price is ₩34450.00. Its book value per share for the quarter that ended in Dec. 2023 was ₩3,673.45. Hence, today's PB Ratio of Hanall Biopharma Co is 9.38.

During the past 13 years, the highest P/B Ratio of Hanall Biopharma Co was 17.95. The lowest was 2.28. And the median was 6.85.


Hanall Biopharma Co Book Value per Share Historical Data

The historical data trend for Hanall Biopharma Co's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hanall Biopharma Co Book Value per Share Chart

Hanall Biopharma Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,743.77 3,541.94 3,192.81 3,319.30 3,673.45

Hanall Biopharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,319.30 3,271.02 3,497.45 3,899.62 3,673.45

Competitive Comparison of Hanall Biopharma Co's Book Value per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Hanall Biopharma Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hanall Biopharma Co's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hanall Biopharma Co's PB Ratio distribution charts can be found below:

* The bar in red indicates where Hanall Biopharma Co's PB Ratio falls into.



Hanall Biopharma Co Book Value per Share Calculation

Hanall Biopharma Co's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(186,218-0)/51
=3,673.45

Hanall Biopharma Co's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(186,218-0)/51
=3,673.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Hanall Biopharma Co  (XKRX:009420) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Hanall Biopharma Co Book Value per Share Related Terms

Thank you for viewing the detailed overview of Hanall Biopharma Co's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Hanall Biopharma Co (XKRX:009420) Business Description

Traded in Other Exchanges
N/A
Address
12 Bongeunsa-ro 114-gil, Daewoong Building, 3rd Floor, Gangnam-gu, Seoul, KOR
Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.

Hanall Biopharma Co (XKRX:009420) Headlines

No Headlines